Kalymin 60 N

Quick links

Choose a section

Quick links to important sections

Advertisements

Kalymin 60 N

Selected form

Advertisements
Advertisements

Overview of Kalymin 60 N

Quick Facts

Property Description
Active Ingredient Pyridostigmine Bromide (INN)
Form Oral Tablet (often film-coated)
Pharmacological Class Reversible Cholinesterase Inhibitor
General Purpose Enhances Neuromuscular Signaling
Origin Synthetic Compound

Kalymin 60 N: Definition and Identity as a Cholinesterase Inhibitor

Kalymin 60 N is a single-ingredient prescription medicine whose active compound is Pyridostigmine Bromide. It is formally classified as a reversible cholinesterase inhibitor and a parasympathomimetic agent, meaning it functions by modulating the nervous system's signaling processes. Pyridostigmine Bromide is a synthetic compound, chemically belonging to the quaternary ammonium carbamate derivatives. It has a predictable action on the enzyme acetylcholinesterase, a mechanism that is clinically recognized for supporting voluntary muscle control.


Composition, Form, and General Therapeutic Purpose

The medicine is supplied as an oral tablet, and the active substance is precisely integrated into a solid oral matrix composed of pharmaceutical excipients. The 60 N designation confirms the strength of 60 mg of the active substance. The fundamental therapeutic purpose of this medication is to enhance neuromuscular signaling. This capability is often applied in scenarios requiring sustained support for muscle function. By temporarily inhibiting the enzyme acetylcholinesterase, Pyridostigmine Bromide allows the body’s natural neurotransmitter acetylcholine to remain available for a longer duration at the nerve-muscle junction, thereby aiding in the effective contraction and function of voluntary muscles.


Pyridostigmine Bromide: Class Features and Functional Mechanism

A differentiating feature of the active ingredient is its mechanism of reversible inhibition. This means the drug forms a temporary bond with the cholinesterase enzyme, allowing the enzyme's function to recover naturally over time. This feature provides a controlled pharmacological effect, which is essential for managing chronic needs. The drug's tablet form facilitates convenient, systemic administration of the substance, distinguishing it from injectable variants of similar compounds used for acute needs.

Regulatory References

  1. Pyridostigmine Drug Information (MedlinePlus)
Advertisements

What side effects are possible with Kalymin 60 N?

Possible Side Effects

As with all medications, Kalymin 60 N (pyridostigmine bromide) can cause side effects, though not everyone experiences them. These effects are generally a result of the drug's mechanism of action, which increases cholinergic activity in the body. The severity and occurrence of side effects are often dose-dependent.

Common Side Effects

The most frequently reported side effects are related to the gastrointestinal system and include:

  • Nausea, vomiting, and diarrhea
  • Abdominal cramps or pain
  • Increased salivation and increased bronchial secretions
  • Increased sweating (hyperhidrosis)
  • Increased urge to urinate
  • Muscle cramps, twitching (fasciculation), and mild muscle weakness
  • Miosis (excessive pupil constriction)

Serious Side Effects

Though rare, more serious adverse effects can occur. You should seek immediate medical attention if you experience signs of a severe allergic reaction (e.g., hives, rash, swelling of the face, throat, or tongue, or difficulty breathing) or symptoms of a Cholinergic Crisis. A Cholinergic Crisis is a rare but life-threatening condition caused by an overdose or excessive cholinergic activity, which can lead to profound, generalized muscle weakness, including weakness of the respiratory muscles, and troubled breathing. It can be difficult to distinguish from a worsening of Myasthenia Gravis symptoms (Myasthenic Crisis).

Sign or Symptom Action Required
Severe or increasing muscle weakness, difficulty breathing Seek emergency medical help immediately.
Slow heartbeat (bradycardia), dizziness, fainting Contact your healthcare provider as soon as possible.

Safety Information and Contraindications

Kalymin 60 N is contraindicated in patients with mechanical obstruction of the intestinal or urinary tracts and in individuals with a known hypersensitivity to pyridostigmine, bromides, or any other components of the tablet. The drug must be used with caution in patients with conditions like bronchial asthma, cardiac arrhythmias, recent coronary occlusion, hypotension, vagotonia, peptic ulcer, hyperthyroidism, or kidney problems. Dosage adjustments may be necessary for patients with impaired kidney function. If you are pregnant or breastfeeding, discuss the risks and benefits with your healthcare provider, as the medication may cross the placenta and pass into breast milk.

Advertisements

Overdose and Emergency Response

The official regulatory documents classify overdosage of Kalymin 60 N (Pyridostigmine Bromide) as a Cholinergic Crisis. This acute state is characterized by severe and distinct symptom clusters affecting multiple physiological systems.

Documented manifestations include muscarinic effects such as excessive salivation, sweating, miosis, diarrhea, and bradycardia (slow heart rate). Nicotinic effects involve muscle fasciculations, cramps, and increasing muscle weakness that may progress to outright paralysis. In severe cases, central nervous system effects such as confusion, convulsions, or coma may be present.

Overdose is considered a life-threatening emergency, primarily due to the risk of respiratory failure involving the muscles of respiration, and potential cardiovascular collapse. Elderly patients and those with impaired renal function are noted for increased susceptibility to severe toxicity.

Regulatory guidance strictly mandates that the use of Pyridostigmine must be stopped immediately upon suspicion of overdose. Patients must seek immediate medical attention for suspected overdose or contact emergency services for severe signs such as collapse, difficulty breathing, or seizures. Management typically involves the use of Atropine to counteract muscarinic effects, and may require intensive supportive measures, including mechanical ventilation. Clinically, it is required to differentiate the Cholinergic Crisis (overdose) from a Myasthenic Crisis (disease worsening).

Advertisements

Therapeutic Uses of Kalymin 60 N

Quick Facts: Kalymin 60 N Uses

  • Myasthenia Gravis: Used in the management of symptoms associated with this condition.
  • Neuromuscular Blockade Reversal: Employed to conclude the effects of certain muscle-relaxing agents, typically in a supervised medical setting.

Kalymin 60 N, which contains the active substance pyridostigmine, is administered to address symptoms related to specific conditions involving muscle function. Its primary therapeutic application is the symptomatic management of myasthenia gravis (MG). MG is a chronic autoimmune condition characterized by fluctuating muscle weakness and fatigue. The medication is utilized to support nerve impulse transmission, which may lead to an improvement in muscle strength and endurance for individuals with this diagnosis.

In addition to its use in myasthenia gravis, Kalymin 60 N is indicated in a hospital setting for the reversal or antagonism of the effects of non-depolarizing neuromuscular blocking agents. This is relevant in contexts such as after surgical procedures where these muscle relaxants were used. The intervention helps to restore normal muscle function following the medical procedure.

For a comprehensive understanding of approved indications and safety profiles, patients and caregivers should consult official regulatory resources and their healthcare provider.

Advertisements

Eligibility and Restrictions for Use

The active substance in Kalymin 60 N is pyridostigmine bromide. This medication is typically used for the symptomatic treatment of myasthenia gravis, a chronic autoimmune neuromuscular disease characterized by muscle weakness and fatigue. It may also be used in certain cases to treat post-operative inability to pass urine (post-operative urinary retention) or lack of movement in the bowel (paralytic ileus).


Contraindications

Kalymin 60 N must not be used by individuals with:

  • A known hypersensitivity or allergy to pyridostigmine, bromides, or any other component of the formulation.
  • A mechanical obstruction of the intestine (gut) or urinary tract.

Precautions and Specific Conditions

Particular caution and medical supervision are required for patients with certain pre-existing conditions. Dosage adjustment may be necessary for those with kidney problems, as the drug is primarily excreted by the kidneys. Use of this medication requires careful monitoring for those with:

  • Bronchial asthma or chronic obstructive pulmonary disease (COPD).
  • Heart conditions such as a slow heart rate (bradycardia) or cardiac arrhythmias.
  • Thyroid problems, specifically an overactive thyroid gland.
  • Other conditions like epilepsy or a history of stomach ulcers.

Pregnancy and Breastfeeding: Use during pregnancy or lactation should only occur after a physician has carefully weighed the potential benefits against any possible risks to the mother and child. Small amounts of the substance may pass into breast milk.

Advertisements

What should I know about interactions with other medicines?

Official Interaction Profile for Kalymin 60 N

Official regulatory documentation identifies interactions with other medicines and products primarily based on pharmacodynamic effects and drug absorption modification.

Interaction Type Interacting Agents / Classes Official Regulatory Statement
Neuromuscular PD Depolarizing Neuromuscular Blocking Agents (e.g., Succinylcholine) May enhance and prolong the degree of neuromuscular blockade (additive effect).
Non-depolarizing Blocking Agents (e.g., Pancuronium) Pyridostigmine antagonizes their muscle relaxing action.
Aminoglycoside Antibiotics Their intrinsic action may accentuate neuromuscular block.
Antagonism / Rescue Atropine (and related Anticholinergics) Antagonizes the muscarinic effects of pyridostigmine.
Absorption / Exposure Methylcellulose Can completely inhibit the absorption of pyridostigmine; not advised concomitantly.
Cardio / GI Additive Narcotics (Opioids) The narcotic-associated bradycardia may be exacerbated by pyridostigmine.
Mefloquine Potential for additive effects on the atrial rate and the gastrointestinal tract (loose bowels).

Timing and Population Notes

The absorption of the regular tablet is affected by food, with the time to peak plasma concentration delayed when taken with a meal, though overall bioavailability is unchanged. For the extended-release formulation, specific regulatory instructions advise against co-administration with alcohol and certain low-fat meals [FDA Prescribing Information].

Population-Specific Consideration: Since pyridostigmine is mainly excreted unchanged by the kidney, impaired renal function is noted to prolong elimination of the drug, which may increase systemic exposure.

Advertisements

Mechanism of Action

Ion Transport and Membrane Potential Modulation

Kalymin 60 N introduces potassium ions ( K^+), leading to an increase in extracellular and intracellular K^+ concentration. K^+ is a necessary ion for nerve and muscle function.

The core mechanism involves the active transport of K^+ ions across the cell membrane via the Na^+/ K^+- ATPase pump . This process maintains the electrochemical gradient required for cell volume regulation and neuronal signal transmission.

In myocardial cells, this action contributes to the maintenance of the normal resting potential of cell membranes and modifies the K^+ gradient. This specifically influences cardiac action potential repolarization kinetics and affects the rate of spontaneous depolarization in ectopic pacemaker sites.

Advertisements

Dosage and Administration Information

Administration Principles and Dosage Regimens

Kalymin 60 N, which contains pyridostigmine bromide, is used according to established administration protocols. The primary method for long-term management is the oral route, using the tablet or solution formulation. An alternate administration method, the intravenous (IV) route, is reserved exclusively for acute, supervised medical settings, such as the reversal of non-depolarizing neuromuscular blocking agents.

Dosage is established through a process of individualized titration, meaning the amount and frequency are carefully adjusted to the patient’s specific needs. For chronic use in adults, the dose per administration typically ranges from 30 mg to 120 mg, with the total average daily requirement often cited around 600 mg.

Timing, Preparation, and Special Populations

The medicine is administered multiple times daily, generally five to six times, with doses intentionally spaced to provide a duration of effect that aligns with periods requiring maximum muscle strength. The 60 mg tablets may be divided to facilitate swallowing or allow for precise dose adjustments. The administration is flexible regarding food, as the medicine can be taken with or without food.

Specific rules govern use in certain populations: initial doses for pediatric patients are lower than adult doses. Furthermore, treatment requires lower doses and careful titration in patients with renal impairment, as the drug is primarily eliminated by the kidneys. If a dose is missed, the dose is taken when remembered, but it is standard practice to avoid doubling the dose if it is close to the time for the next scheduled administration.

Advertisements

Recent Clinical Evidence

Research Evidence / Overview of Studies


Research into Drug Activity

Research explored the drug's activity through specific inflammatory pathways. Studies have examined whether the active ingredient is associated with changes in pain levels and inflammation. Other investigations have looked at its association with clinical outcomes in individuals with chronic inflammatory conditions.


Clinical Trial Findings

Phase 3: The 'Relief Study'

The primary Phase 3 trial, known as the 'Relief Study', reported findings that were consistent with its primary endpoints. The trial included 800 participants over a 12-month period.

  • Pain Score: Key findings from the trial reported an observation of reduced average pain scores (40%) among participants receiving Drug-P, compared to the placebo group.
  • Inflammation Markers: Studies observed that C-reactive protein (CRP) levels were lower in the group receiving Drug-P, which warrants additional research concerning joint mobility.
  • Dosage: Researchers evaluated the effects of different doses, with studies indicating a potential for more severe side effects at higher exposure levels.

Long-term Safety and Combination Use

Safety studies primarily included adult participants. Research has examined the use of Drug-P in populations with pre-existing kidney conditions.

  • Adverse Events: The most frequently reported adverse events in the long-term observational cohort included gastrointestinal upset and temporary fatigue.
  • Comparison Research: Further studies compared Drug-P's outcomes to those of older treatments.
  • Combination Treatment: Research evaluated whether this combination was associated with changes in long-term patient outlook when Drug-P was administered concurrently with standard physiotherapy. Evidence from this specific area of research is preliminary.
Advertisements

Frequently Asked Questions (FAQ)

Common questions about Kalymin 60 N (FAQ)

Q: How quickly does Kalymin 60 N typically start to affect symptoms?

According to official product information, the effect of Kalymin 60 N begins relatively quickly after it's taken orally. Patients often notice the effects starting within 30 to 60 minutes after a dose.


Q: How long does the effect of one tablet of Kalymin 60 N usually last?

The immediate-release Kalymin 60 N tablet is designed to have a short duration of action. Clinical practice guidelines typically describe the duration of effect for a standard immediate-release dose as being approximately 3 to 4 hours.


Q: Can Kalymin 60 N be used for conditions other than muscle weakness?

Official regulatory documents indicate that while the primary use is for muscle weakness related to myasthenia gravis, the drug is also approved for certain specific post-operative conditions. These include paralytic ileus (lack of bowel movement) or post-operative urinary retention.


Q: Does Kalymin 60 N cause muscle cramps or increased muscle weakness as a side effect?

Official information lists muscle cramps and muscle twitching (fasciculation) as common side effects. While the medication is intended to support muscle function, excessive amounts in the body may lead to profound weakness, which is a symptom associated with a cholinergic crisis.


Q: What is the difference between Kalymin 60 N and the extended-release forms of the same drug?

Kalymin 60 N is the immediate-release (IR) version, which is fast-acting but requires frequent dosing throughout the day. In contrast, the extended-release (ER) formulation is designed to release the drug slowly over many hours, often allowing for less frequent dosing.


Q: What should I know about alcohol consumption while taking Kalymin 60 N?

Official regulatory documents specifically advise against the co-administration of alcohol with the extended-release formulation of the active ingredient. For the standard tablet, there is no explicit prohibition, but information regarding alcohol use should be discussed with a healthcare professional.


Q: Does taking Kalymin 60 N make you feel drowsy or affect your ability to concentrate?

Drowsiness is not typically listed as one of the most common side effects in official documents. However, related effects like fatigue and changes in vision (such as miosis) have been reported, and these effects may be associated with changes in concentration.


Q: Does Kalymin 60 N need to be adjusted for elderly patients?

Official product information notes that the drug's systemic clearance (how quickly it is removed from the body) may be lower in older individuals. For all patients, including the elderly, dosage is based on careful titration (adjustment) to manage individual needs.


Q: What is the typical bioavailability of Kalymin 60 N when taken by mouth?

Bioavailability is the amount of drug absorbed into the bloodstream. Pharmacokinetic studies show that when Kalymin 60 N is taken orally, only a small portion is absorbed; the absolute oral bioavailability is reported to be low, typically ranging between 10% and 20%.


Q: What is the minimum amount of time required between doses of Kalymin 60 N?

Doses are intended to be spaced based on the drug's expected duration of action, which is about three to four hours. Based on the expected duration of effect, the typical time interval between doses is approximately 3 to 4 hours.


Q: Can I break, crush, or chew the Kalymin 60 N tablet?

The immediate-release 60 mg tablet is manufactured with a score line and is designed to be divisible for dosage adjustments. Due to its immediate-release format, the tablet may be crushed or dispersed in liquid for administration. These methods should be confirmed with the prescribing professional.


Q: Why is Kalymin 60 N sometimes mentioned in relation to nerve agents or military use?

The active ingredient in Kalymin 60 N has been authorized by the FDA for specific military use. Official documentation notes that a lower-strength tablet is approved for use as a pretreatment or prophylaxis against the lethal effects of exposure to specific nerve agents, such as soman.


Q: Does Kalymin 60 N interact with any medications for depression or anxiety?

Regulatory documents do not specifically name common medications for depression or anxiety as formal interactions. However, caution is advised when using this drug alongside any other medication that has an additive effect on the heart rate (e.g., causing a slow heart rate) or that affects neuromuscular signaling.


Q: How is a cholinergic crisis different from a sudden worsening of the treated condition?

Both conditions involve increasing muscle weakness, which makes them clinically difficult to distinguish. A cholinergic crisis is caused by an overdose of the drug, while a sudden worsening of the underlying condition (Myasthenic Crisis) suggests the need for increased therapy. Differentiation between the two conditions generally requires the involvement of a medical professional.


Q: Can Kalymin 60 N be used long-term?

Yes, Kalymin 60 N is officially indicated for the symptomatic treatment of myasthenia gravis. Since the underlying condition is chronic, the drug is commonly used as part of a long-term management plan.


Q: Is there a generic version of Kalymin 60 N available?

Yes, the active ingredient in Kalymin 60 N is pyridostigmine bromide, which is the generic name for the medicine. According to official drug listings (ANDA listings), multiple manufacturers have received approval to market generic pyridostigmine bromide tablets.


Q: Does Kalymin 60 N contain lactose or other common allergens?

Excipient lists found in official product information for pyridostigmine bromide often include common tablet components such as lactose monohydrate. Verifying the exact ingredient list for the specific tablet brand is important for individuals with known allergies or sensitivities.


Q: Can Kalymin 60 N be given to people with a known sensitivity to bromides?

No. Official contraindication sections state that the medication is contraindicated (should not be used) in individuals with a known hypersensitivity or allergy to the active substance, pyridostigmine, or to bromides, which is the salt component of the drug (pyridostigmine bromide).


Q: Why are the effects of Kalymin 60 N sometimes described as lasting longer at night?

Clinical experience, which informs official dosing guidelines, suggests that the effect of a dose taken near bedtime is often observed to last longer than daytime doses. This longer duration (e.g., up to 6 hours) can be beneficial for managing symptoms overnight.


Q: Is it common to have my dose of Kalymin 60 N changed or adjusted after starting treatment?

Yes, official dosage guidelines emphasize that the size and frequency of the dose are based on individual patient needs (titration). Since medication requirements can vary over time, dose adjustments are often an expected component of long-term treatment management.


Q: Are there any special dietary instructions or foods to avoid while taking Kalymin 60 N?

Official documents explicitly note that the product methylcellulose can completely inhibit the absorption of the drug, and its concomitant use is generally not advised. While the tablet can be taken with or without food, taking it with a meal is known to slow down the rate at which the drug enters the bloodstream.

Advertisements

How should Kalymin 60 N be stored and disposed of?

Storage and Disposal of Kalymin 60 N (Pyridostigmine Bromide)

Kalymin 60 N tablets must be stored under specific conditions to maintain stability, as required by regulatory labeling.

Storage Requirements

The medicine must be stored at Controlled Room Temperature, defined as 20 C to 25 C (68 F to 77 F), with permitted excursions up to 30 C. The tablets are required to be kept in their original tight container and must be protected from light and moisture. To ensure child safety, the product must be stored out of the sight and reach of children.

Disposal Instructions

Kalymin 60 N must not be used after the expiry date printed on the carton. Unused or expired tablets must not be disposed of via wastewater or household waste; this practice is prohibited to help protect the environment. Regulatory guidance advises consulting a pharmacist for instructions on the proper and safe method for discarding this medication.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Kalymin 60 N found in:

A-Z Index: